絞り込み

16732

広告

Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?

著者 Palmerini E , Chawla NS , Ferrari S , Sudan M , Picci P , Marchesi E , Leopardi MP , Syed I , Sankhala KK , Parthasarathy P , Mendanha WE , Pierini M , Paioli A , Chawla SP
Eur J Cancer.2017 Mar 16 ; 76():118-124.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (190view , 0users)

Full Text Sources

Medical

Giant-cell tumours of bone (GCTB) are RANK/RANK-ligand (RANKL) positive, aggressive and progressive osteolytic tumours. Denosumab, a RANKL inhibitor, was FDA-approved for adults and skeletally mature adolescents with unresectable GCTB or when surgical resection is likely to result in severe morbidity. Data on long-term toxicity and activity of denosumab monthly 'GCTB-schedule' (120 mg per 12/year, 1440 mg total dose/year) are lacking.
PMID: 28324746 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード